Eton Pharmaceuticals price to sales ratio ETON
Market value divided by revenue over the last twelve months, since 2020.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 13.0×
- May 2025
- 7-year median
- 4.8×
- 7-year range
- 2.5× to 194×
- Peer median
- 1.8×
Eton Pharmaceuticals' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in May 2025, at 13.0×.
On the days it had one over the last 7 years, its median was 4.8×, from 2.5× in Jun 2024 to 194× in Jun 2020.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2025 | 13.0× | 9.1× | 13.4× |
| 2024 | 9.7× | 2.5× | 10.1× |
| 2023 | 3.4× | 2.7× | 5.3× |
| 2022 | 3.8× | 3.2× | 6.8× |
| 2021 | 6.7× | 5.8× | 17.3× |
| 2020 | 189× | 57.8× | 194× |
Against its peers
Companies in Drug Manufacturers - General nearest Eton Pharmaceuticals' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| ETONEton Pharmaceuticals | n/m |
| PCRXPacira BioSciences | 1.9× |
| ANABAnaptysbio | n/m |
| PAHCPhibro Animal Health | 1.0× |
| ANIPANI Pharmaceuticals | 1.7× |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 1.5× |
| HRMYHarmony Biosciences | 2.2× |
| PBHPrestige Consumer Healthcare | 2.0× |
| ABUSArbutus Biopharma | 4.6× |
| COLLCollegium Pharmaceutical | 0.9× |
| Peer median | 1.8× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Eton Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.